Abstract: The invention provides vectors containing a multiple cloning site comprising a PrS tag or a PrS2 tag from Myxococcus xanthus. Methods are provided for enhancing solubility of a target protein using Protein S tagged target fusion proteins.

Abstract: The invention relates to methods of use of SET1 proteins or functional equivalents thereof. More particularly the invention relates to the use of SET1 proteins or functional equivalents thereof in procedure, for identification and/or isolation of IgA and the scrum complement factor C5.

Abstract: The invention relates to methods of treating a disease or condition, wherein expression or activity of soluble CLCA1 is up-regulated, by administering inhibitors of soluble CLCA1. The invention also relates to methods of isolating soluble CLCA1 from a bodily fluid.

Abstract: The subject of the invention is separation on a solid support by multi-column sequential selective retention in order to separate a product of interest from a solution containing such a product of interest, by passing this solution over a fixed chromatographic resin bed comprising at least three zones, liquid flow means being placed between adjacent zones and between the last zone and the first zone, this process comprising several sequences, each sequence comprising at least one step chosen from an absorption step, a rinsing step and a desorption step, carried out either simultaneously or not, each following sequence is carried out by the displacement of the fronts in the zones towards the downstream end substantially of the same increment before the periodic displacement of the points of introduction and of withdrawal, characterized in that the process includes a sub-sequence without injection of the charge.

Abstract: A method for affinity capturing target molecules is disclosed, comprising obtaining a sample comprising a target molecule; and, in the presence of a denaturing agent; affinity capturing the target molecule with a single chain affinity molecule or antigen binding portion thereof that specifically binds the target molecule, wherein the affinity molecule or antigen binding portion thereof is immobilized on a support.

Abstract: The present invention relates to a method for separating a material that has affinity to an antibody by using a protein-antibody conjugate with modified partition characteristics, more precisely a method for affinity separation to separate a material specifically binds to an antibody, in which an antibody is conjugated to a protein to modify partition characteristics of the protein-antibody conjugate. The method of the present invention can be effectively and widely used as a safe and efficient separation method for biomolecules since it takes advantages of safe aqueous two-phase extraction system and high selective molecular specific conjugation.

Abstract: A novel polypeptide ligand, p30, or LIGHT, for herpes virus entry mediator, HVEM, is provided. LIGHT is useful for modulating immune responses and in inhibiting infection and/or subsequent proliferation by herpesvirus. HVEM fusion proteins are also provided. Methods for treating subjects with lymphoid cell disorders, tumors, autoimmune diseases, inflammatory disorders or those having or suspected of having a herpesvirus infection, utilizing p30 and the fusion proteins of the invention, are also provided.

Abstract: The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of Trypanosoma cruzi.

Abstract: Methods are disclosed for use of apatite chromatography, particularly without reliance upon phosphate gradients, for purification or separation of at least one intact non-aggregated antibody, or at least one immunoreactive antibody fragment, from an impure preparation. Integration of such methods into multi-step procedures with other fractionation methods are additionally disclosed.

Abstract: The present invention relates generally to anti-MHC assay methodologies utilizing functionally active, recombinantly produced, and truncated individual soluble MHC trimolecular complexes that are linked to a substrate. The methods include reacting a sample with the substrate having the MHC trimolecular complex linked thereto, whereby antibodies specific for the at least one MHC trimolecular complex linked to the substrate are removed from the biological sample.

Abstract: The present invention relates to phosphopeptide isolation and enrichment, particularly to a highly selective and specific phosphopeptide enrichment method. The method mentioned in the invention is based on the strong interaction between zirconium phosphonate and phosphopeptide. Zirconium phosphonate is immobilized on the surface of matrix for phosphopeptide enrichment. Zirconium phosphonate could be immobilized on chip surface, it can also be immobilized on chromatographic matrix for isolation and purification of phosphopeptides. The method shows high specificity for phosphopeptides, it can be applied to purify and enrich low abundance phosphopeptide from biological samples.

Abstract: Methods, compositions, and kits related to the use of multi-ligand affinity chromatography are described. The methods include those related to identification of glycoprotein panels for analyzing and diagnosing disease.

Abstract: The invention provides systems, methods and kits for the separation and/or purification of at least two cellular components selected from genomic DNA, RNA and proteins. The method includes first lysing a biological sample to generate an aqueous solution containing the cellular components; then applying the aqueous solution to a first mineral support under conditions for genomic DNA to bind; and collecting the flowthrough which contains unbound total RNA and proteins. The method further includes applying the flowthrough to a second mineral support under conditions for RNA to bind, and collecting the flowthrough which contains proteins. The genomic DNA and total RNA bound can be eluted while the protein in the flowthrough can be further purified. Further the total RNA isolated could be used to isolate small RNA such as microRNA.

Abstract: The present invention relates to methods and compositions for the identification of cancer markers. In particular, the present invention provides methods and compositions for the identification of glycosylated proteins and protein glycosylation patterns. The present invention further provides cancer markers identified using the described methods.

Abstract: The invention relates, inter alia, to the use of neuregulin-? as a target in a screening method for active compounds, in particular for exerting an influence on changes in calcium concentration which are mediated by glutamate receptors. The invention furthermore relates to the use of neuregulins, preferably a neuregulin isoform having an isoelectric point in the range from pH 4.3 to 5.0, as a target for detecting and/or exerting an influence on neuronal processes, in particular for exerting an influence on long-term memory. Neuregulins, in particular neuregulin-? and also substances which exert an influence on the status, i.e. the expression and/or post-translational modification, of neuregulin-?, can therefore be used as agents for controlling the course of, treating and/or alleviating neuronal diseases, e.g. Alzheimer's disease.

Abstract: High affinity antibodies for binding epitopes of BoNT/A and hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting BoNT/A in a sample.

Abstract: The invention is directed to novel uses of Factor H, in particular in antibody-independent chronic nephropathies, e.g. in tubulointerstitial fibrosis (TIF). The invention is further directed to novel large scale manufacturing processes for Factor H.

Abstract: Methods for producing improved anti-human thymocyte immunoglobulins from specific-pathogen-free animals are provided, without the need for an adsorption step on human tissues and the consequent drawbacks of such a step.

Abstract: A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like. The NT-proBNP ELISA assay test employs the sandwich ELISA technique to measure circulating NT-proBNP in human plasma. In order to obtain antibodies with specific binding properties for targeted amino acid sequences within human proBNP, recombinant human proBNP (or rhproBNP) was expressed and purified for use as an immunogen. Polyclonal antibodies (PAb) to specific amino acid sequences were subsequently purified from goat serum by sequential affinity purification. Monoclonal antibodies were raised against specific polypeptides. Recombinant human NT-proBNP (or rhNT-proBNP) was expressed and purified in order to obtain material for use in calibration of a quantitative method for measurement of human NT-proBNP.

Abstract: The present invention relates to a process for purifying an interleukin-15/Fc fusion protein from a composition, which process comprises a) applying the composition to an affinity chromatography column and eluting a first IL-15/Fc eluate from the column and b) applying the eluate of step a) to an ion exchange chromatography column and eluting a second IL-15/Fc eluate from the column; and to a purified interleukin-15/Fc fusion protein and a composition, in particular a pharmaceutical composition, comprising such a fusion protein.

Abstract: A method for reducing leaching of protein A during protein A affinity chromatography is described which involves reducing temperature or pH of, or by adding one or more protease inhibitors to, a composition that is subjected to protein A affinity chromatography.

Abstract: A method for the purification of immunoglobulins by ion exchange chromatography is described. The chromatographic method uses a weak ion exchange resin and a single step elution process for the purification of an immunoglobulin. Additionally a method for the determination of the salt concentration for the single step elution of an immunoglobulin from an ion exchange resin is described.

Abstract: A method for purifying bioactive substances includes the steps of: causing a bioactive substance having histidine units to contact media, each constituted by a substrate, ligands which are physically attached to the surface of the substrate, and Cu(II) or Fe(II) metal ions which are covalently bonded to the ligands; causing the bioactive substance to covalently bond with the metal ions via the histidine units; and washing the media with an amount of 1 nmol/L to 10 mmol/L imidazole derivative solution 60 times the volume of the media or greater. In the case that the metal ions are Cu(II), the bioactive substance which has covalently bonded with the Cu(II) via the histidine units are recovered by one of a 10 mmol/L to 1 mol/L imidazole derivative solution and a 0.5 mmol/L to 5 mol/L EDTA solution.

Abstract: The invention relates to methods of producing Protein A without contamination of the Protein A by animal products. The invention also relates to a vegetarian fermentation media in which Staphylococcus aureus is grown to produce a vegetarian Protein A. The invention further relates to a vegetarian Protein A and the use of a vegetarian Protein A in therapeutic and prophylactic methods.

Abstract: An isolated polynucleotide is provided, comprising a nucleic acid sequence encoding a soluble polypeptide which comprises an amino acid sequence of an N-terminus domain of CXCR4 and devoid of a CXCR4 extracellular domain selected from the group consisting of ECL1, ECL2 and ECL3, the soluble polypeptide being capable of binding SDF-1. Also provided are methods of using such a nucleic acid sequence such as for the treatment of cancer.

Abstract: The invention is directed to virus-like particles (VLPs) of an RNA bacteriophage that (a) comprises a coat polypeptide of said phage modified by insertion of a heterologous peptide that is displayed on said VLP and (b) encapsidates said bacteriophage mRNA as well as populations of these VLPs, and their uses. The invention is further directed to VLPs that encapsidate heterologous substances, as well as populations of these VLPs and their uses.

Abstract: The invention provides a process for the purification recombinantly expressed, self-assembled VLP from the homogenate of a bacterial host, wherein the process can be scaled up to a commercial production scale in a cost effective manner. The process comprises a first chromatography using an anion exchange matrix, a second chromatography using hydroxyapatite and, optionally, a size exclusion chromatography. VLP preparations obtained by the process of the invention are essentially free of endotoxin contaminations.

Abstract: The present invention relates to a method for detecting and/or unifying proteins and/or biomolecule or protein complexes, as well as fusion proteins, nucleic acids, vectors and cells suitable for this method.

Abstract: A polypeptide comprising a SAM domain, the sequence of said SAM domain being as set forth in SEQ ID NO: 33.

Abstract: The present invention is relates to non-diffusible globular A?(X-38 . . . 43) oligomers (“globulomers”) or derivatives thereof, methods for enriching said globulomers or derivatives, compositions comprising said globulomers or derivatives, antibodies and aptamers having specificity for said globulomers or derivatives, methods for preparing such antibodies and aptamers, uses of said globulomers or derivatives, or of said antibodies or aptamers for diagnostic, therapeutic and other purposes, and corresponding methods using said globulomers or derivatives, or said antibodies or aptamers.

Abstract: This invention relates to methods of analysis, and in particular to methods for the preliminary fractionation of samples in which low abundance molecules of interest, for example proteins, polysaccharides or fatty acids, are present together with more abundant molecules of little or no interest. In particular, the invention relates to methods of depletion of high abundance proteins from biological samples. Products and kits for use in the method are also disclosed, and form part of the invention. In one aspect, the invention provides a method of depleting a high-abundance molecule from a biological sample, comprising the steps of a) subjecting the sample to affinity depletion using an affinity support with high affinity for a high abundance molecule, and/or b) immunodepletion using an affinity support coupled to an antibody directed against whole or previously fractionated plasma or serum.

Abstract: The present invention relates to intercellular adhesion molecules (ICAM-1) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.

Abstract: A system and method for cleanup of biological samples from contaminants prior to spectroscopy analysis. The system includes a support configured to hold a sample including a liquid having at least one group of biological molecules with a surface of the support binding the molecules at a surface tension angle to the liquid of less than 180 degrees. The system includes an evaporator configured to evaporate liquid from the support, a solvent applicator configured to apply a solvent for dissolution of the contaminants in the sample, and a solvent removal device configured to remove applied solvent from the sample and thereby at least partially remove the contaminants.

Abstract: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-? at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides.

Abstract: A method for reducing leaching of protein A during protein A affinity chromatography is described which involves reducing temperature or pH of, or by adding one or more protease inhibitors to, a composition that is subjected to protein A affinity chromatography.

Abstract: This invention relates to polypeptides which bind to EGFR family receptors and to applications of those polypeptides in medicine, veterinary medicine, diagnosis diagnostics and imaging.

Abstract: A method is provided for separating a protein from one or more other proteins using hydroxyapatite chromatography in which the protein does not bind to hydroxyapatite but the other protein(s) does. In some embodiments, a second protein affixed to a solid support has been used previously to purify the protein by affinity chromatography, and small amounts of the second protein are introduced in the sample during this process. The protein being purified can comprise at least one constant antibody immunoglobulin domain. The second protein can bind to proteins comprising such a domain.

Abstract: The present invention provides a method for recombinant production, recovery and purification of endostatin protein. This method may be employed for large scale recovery and purification of recombinantly-produced endostatin protein.

Abstract: The invention belongs to the field of functional proteomics and, more particularly, to the field of protein aggregation. Described are methods for interfering with the function of a target protein and uses a non-naturally, user-designed molecule, designated as interferor, that has a specificity for a target protein and that induces aggregation upon contact with the target protein. The invention also discloses such interferer molecules and their use in therapeutic applications.

Abstract: The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.

Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.

Abstract: A novel method for purifying antibody and other product protein concomitant with removing aggregates made up from single product protein species is devised.

Abstract: The invention provides methods of preparation of lipoproteins from a biological sample, including HDL, LDL, Lp(a), IDL, and VLDL, for diagnostic purposes utilizing differential charged particle mobility analysis methods. Further provided are methods for analyzing the size distribution of lipoproteins by differential charged particle mobility, which lipoproteins are prepared by methods of the invention. Further provided are methods for assessing lipid-related health risk, cardiovascular condition, risk of cardiovascular disease, and responsiveness to a therapeutic intervention, which methods utilize lipoprotein size distributions determined by methods of the invention.

Abstract: The present invention relates to a method of isolating target compounds from a liquid, which method including the steps of providing a mobile phase, which contains at least one target compound and wherein the conductivity corresponds to ?0.6 M; contacting the mobile phase with a separation matrix including one or more sulphonamide groups to adsorb one or more target compounds; contacting an eluent with the matrix to release target compound(s), wherein the conductivity of the eluent is reduced as compared to the mobile phase conductivity and the pH is substantially equivalent to the mobile phase pH; and, optionally, recovering at least one target compound or a purified liquid.

Abstract: A polymer substrate functionalized with a functionality comprising at least one cyclic, metal ion coordinating ligand group, the cyclic ligand group comprising at least 3 metal ion coordinating donor atoms independently selected from the group consisting of N, O and S.

Abstract: The invention relates to the process for the isolation and/or purification of biologically active proteins, preferably TNF-alpha or TNF-alpha analogues. The process of the present invention results in the production of high yields of proteins, preferably TNF-alpha or TNF alpha analogues with a purity of greater than 98%. The described process is particularly suitable for the industrial production of proteins, preferably TNF-alpha or TNF-alpha analogues.

Abstract: The present invention relates to a protein found in natural rubber that can induce an allergic reaction in persons who have been sensitised to it. The invention provides for the process of isolating and purifying the protein and describes the characteristics of the protein, including its molecular weight, isoelectric point, amino acid sequence and allergenicity. The invention also describes the isolation and cloning a the DNA that encodes the protein. The production of the recombinant version of the protein using a protein expression vector is described.

Abstract: Methods for stabilizing polypeptides, such as anti-HER2 antibodies, which have been exposed to urea.

Abstract: The invention provides binding reagents that contain a plurality of linked small epitope binding molecules that each recognizes a small epitope, such as small epitope antibodies. The combination of small epitope binding molecules in a binding reagent specifically recognizes and binds to a molecule of interest. The binding reagents may be used for such purposes as detection, quantification, identification, and purification of molecules of interest.

Abstract: The present disclosure relates to a system and method for protein separation including: fractionating a mixture of proteins on a reversed-phase superficially porous stationary phase at a temperature of greater than or equal to about 40° C. to recover a protein in from about 70 to 100 weight percent of the mixture of proteins.